Skip to main content

ENvue Medical, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

FEED$1.03-69.3%Stored close · as of Sep 15, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney (attached to the signature page hereto)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brian Murphy as his true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or any of them or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/ BRIAN MURPHYChief Executive Officer and DirectorMarch 31, 2025
Brian Murphy(principal executive officer)
/s/ STEPHEN BROWNChief Financial OfficerMarch 31, 2025
Stephen Brown(principal financial and accounting officer)
/s/ CHRISTOPHER FASHEKChairman of the Board of DirectorsMarch 31, 2025
Christopher Fashek
/s/ MARTIN GOLDSTEINDirectorMarch 31, 2025
Martin Goldstein
/s/ DORON BESSER, M.D.DirectorMarch 31, 2025
Doron Besser, M.D.
/s/ THOMAS R. MIKADirectorMarch 31, 2025
Thomas R. Mika
/s/ Aurora CassirerDirectorMarch 31, 2025
Aurora Cassirer
/s/ ZEEV ROTSTEINDirectorMarch 31, 2025
Zeev Rotstein, M.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.